Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from intern... A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue. Mostrar más
Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of...
Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data for ULTOMIRIS in generalized myasthenia gravis Patients who transitioned from...
Partnership contributes to the AZ Forest global initiative to plant and maintain 50 million trees worldwide by the end of 2025 AstraZeneca has partnered with The National Fish and Wildlife...
First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs New preclinical authentic ‘live’ virus data from Washington...
First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo’s ENHERTU offer potential to redefine how the disease is classified and treated Positive high-level...
Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful...
Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and...
A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and...
TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting Combination did not increase discontinuations due to adverse events vs...
Based on ground-breaking DESTINY-Breast03 results showing AstraZeneca and Daiichi Sankyo’s ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
Magnum7419
5 minutos hace
Trooperstocks
5 minutos hace
Trooperstocks
5 minutos hace
glenn1919
5 minutos hace
trunkmonk
5 minutos hace
Trooperstocks
6 minutos hace
Trooperstocks
6 minutos hace
Trooperstocks
6 minutos hace
Trooperstocks
6 minutos hace
dexprs
6 minutos hace
Juntao
7 minutos hace
stockprofitter
7 minutos hace
zab
7 minutos hace
AugustaFriends
7 minutos hace
pdmihopefull
7 minutos hace
Screech691
7 minutos hace
Hoghead7
7 minutos hace
Screech691
7 minutos hace
stockprofitter
8 minutos hace
kgw
8 minutos hace
rodeoup
8 minutos hace
downdraft
8 minutos hace
Jetmek_03052
9 minutos hace
Myth
9 minutos hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
